Heart failure Circulatory System Heart failure
Conditions
Interventions
We intend to conduct a double blind, placebo-controlled, randomised, cross-over trial comparing NAC (600 mg once daily [od], effervescent tablet Flumicil®) to placebo in patients with persistent major
Sponsors
Department of Health
Eligibility
Inclusion criteria
Inclusion criteria: Blood samples will be taken to measure N-terminal pro-brain natriuretic peptide (NT-proBNP), tumour necrotising factor (TNF), interleukin-6 (IL-6), soluble tumour necrosis factor receptor 1 (sTNFR1), soluble tumour necrosis factor receptor 2 (sTNFR2). Oxidative stress will be assessed by the measurement of 8-epimer of Prostaglandin F2 (8-iso-PGF2). The effects on the myocardial interstitium will be assessed by measuring 3 degradation markers total membrane metalloproteinase 1 (MMP-1), total tissue inhibitor of metalloproteinase 1 (TIMP 1), and the MMP-1/TIMP 1 complex. As well as 3 extra-cellular matrix serum markers pro-collagen type I carboxy-terminal peptide (P-I-CP), pro-collagen type I amino terminal peptide (P-I-NP), and pro-collagen type III amino terminal peptide (P-III-NP). They will be collected by Dr Windram and members of the nursing staff of the Department of Academic Cardiology Department.
Exclusion criteria
Exclusion criteria: 1. Asthma 2. Known intolerance to NAC 3. Serum creatinine greater than 200 mol/L
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Improvement in left ventricular ejection fraction (LVEF), measured by cine-magnetic resonance imaging. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Symptoms 2. Exercise capacity 3. Natriuretic peptides 4. Serum creatinine 5. Vascular function | — |
Countries
United Kingdom
Outcome results
None listed